Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19-CAR-T in R/R B-cell Tumors
NCT06375161Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), sponsored by Tongji Hospital. Primary endpoint: Incidence of dose-limiting toxicity at 28 days. Started Dec 2023; status: recruiting.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT06375161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375161.